Cargando…

Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers

Detalles Bibliográficos
Autores principales:	Gangadhar, Tara C, Hamid, Omid, Smith, David C, Bauer, Todd M, Wasser, Jeffrey S, Luke, Jason J, Balmanoukian, Ani S, Kaufman, David R, Zhao, Yufan, Maleski, Janet, Leopold, Lance, Gajewski, Thomas F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645566/ http://dx.doi.org/10.1186/2051-1426-3-S2-O7

Ejemplares similares

Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)
por: Mitchell, Tara C., et al.
Publicado: (2018)

Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma
por: Gibney, Geoffrey T., et al.
Publicado: (2019)

Treatment with the IDO inhibitor INCB024360 increased lysis of human tumor cell targets by peptide-specific CTL
por: Jochems, Caroline, et al.
Publicado: (2015)

INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology
por: Yue, Eddy W., et al.
Publicado: (2017)

Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors
por: Luke, Jason J., et al.
Publicado: (2023)

Phase 1 study of epacadostat in combination with atezolizumab for patients with previously treated advanced nonsmall cell lung cancer
por: Hellmann, Matthew D., et al.
Publicado: (2020)

Epacadostat Plus Pembrolizumab and Chemotherapy for Advanced Solid Tumors: Results from the Phase I/II ECHO-207/KEYNOTE-723 Study
por: Powderly, John D, et al.
Publicado: (2022)

Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study
por: Naing, Aung, et al.
Publicado: (2022)

The catalytic inhibitor epacadostat can affect the non-enzymatic function of IDO1
por: Panfili, Eleonora, et al.
Publicado: (2023)

Targeting the tumor microenvironment by liposomal Epacadostat in combination with liposomal gp100 vaccine
por: Tahaghoghi-Hajghorbani, Sahar, et al.
Publicado: (2023)

Phase 1/2 study of epacadostat in combination with durvalumab in patients with metastatic solid tumors
por: Naing, Aung, et al.
Publicado: (2022)

A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma
por: Dummer, Reinhard, et al.
Publicado: (2015)

Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
por: Koblish, Holly K., et al.
Publicado: (2022)

Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types
por: Gangadhar, Tara C, et al.
Publicado: (2015)

Lichen planopilaris associated with pembrolizumab in a patient with metastatic melanoma
por: Cogen, Anna L., et al.
Publicado: (2018)

Suppression and Regression of Choroidal Neovascularization in Mice by a Novel CCR2 Antagonist, INCB3344
por: Xie, Ping, et al.
Publicado: (2011)

INCB, WHO AND UNODC STATEMENT ON ACCESS TO INTERNATIONALLY CONTROLLED MEDICINES DURING COVID-19 PANDEMIC
Publicado: (2020)

First-in-Human Study of INCB062079, a Fibroblast Growth Factor Receptor 4 Inhibitor, in Patients with Advanced Solid Tumors
por: Harding, James J., et al.
Publicado: (2023)

Sphingomyelin-derived nanovesicles for the delivery of the IDO1 inhibitor epacadostat enhance metastatic and post-surgical melanoma immunotherapy
por: Wang, Zhiren, et al.
Publicado: (2023)

INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph(+) acute lymphoblastic leukemia
por: Martinelli, Giovanni, et al.
Publicado: (2022)

Tumor Microenvironment in Oral Cancer Following Neoadjuvant Pembrolizumab: Preliminary Analysis of the Histopathologic Findings
por: Dobriyan, Alex, et al.
Publicado: (2021)

The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells
por: Jochems, Caroline, et al.
Publicado: (2016)

Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers
por: Komiya, Takefumi, et al.
Publicado: (2018)

Retraction: Tumor Microenvironment in Oral Cancer Following Neoadjuvant Pembrolizumab: Preliminary Analysis of the Histopathologic Findings
Publicado: (2022)

Characterization of oncogenic pathways linked with T cell exclusion in urothelial bladder cancer
por: Sweis, Randy F, et al.
Publicado: (2015)

The Bromodomain Inhibitor, INCB057643, Targets Both Cancer Cells and the Tumor Microenvironment in Two Preclinical Models of Pancreatic Cancer
por: Leal, Ana S., et al.
Publicado: (2020)

IDO-1 inhibitor INCB24360 elicits distant metastasis of basal extruded cancer cells in pancreatic ductal adenocarcinoma
por: Buhe, Hada, et al.
Publicado: (2022)

Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program
por: Gangadhar, Tara C., et al.
Publicado: (2017)

Biomarker analysis of on-treatment and at progression biopsies from BRIM7 - a phase 1B trial of combined vemurafenib and cobimetinib treatment in BRAF V600 mutated melanoma
por: Yan, Yibing, et al.
Publicado: (2014)

Updated results and correlative FDG-PET analysis of a phase IB study of vemurafenib and cobimetinib (MEK inhibitor [GDC-0973]), in advanced BRAF(V600)- mutated melanoma (BRIM7)
por: Puzanov, Igor, et al.
Publicado: (2014)

Correction: Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study
Publicado: (2022)

Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies
por: Koblish, Holly, et al.
Publicado: (2018)

Janus kinase 1 inhibitor INCB054707 for patients with moderate‐to‐severe hidradenitis suppurativa: results from two phase II studies
por: Alavi, Afsaneh, et al.
Publicado: (2022)

Therapeutic efficacy of combined blockade of CTLA-4 +/- PD-L1 +/- IDO is associated with re-activation of T cells directly within the tumor microenvironment
por: Spranger, Stefani, et al.
Publicado: (2013)

Challenging the standard of care in advanced melanoma: focus on pembrolizumab
por: Abdul-Karim, Raghad M, et al.
Publicado: (2017)

Differential expression of groEL-1, incB, pyk-F, tal, hctA and omcB genes during Chlamydia trachomatis developmental cycle
por: Mzobe, Gugulethu F., et al.
Publicado: (2021)

The synergy of the XPO1 inhibitors combined with the BET inhibitor INCB057643 in high-grade B-cell lymphoma via downregulation of MYC expression
por: Deng, Manman, et al.
Publicado: (2023)

Evidence implicating the commensal microbiota in shaping anti-tumor immunity in melanoma
por: Sivan, Ayelet, et al.
Publicado: (2014)

Melanoma-intrinsic β-catenin signaling prevents T cell infiltration and anti-tumor immunity
por: Spranger, Stefani, et al.
Publicado: (2014)

INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models
por: Liu, Phillip C. C., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_s9dhh5m74gvjqil8mr6793pup1